La Roche Posay Invisible Fluid SPF50+
For normal to sensitive skin.
Ultra high UVA/UVB protection with an invisible finish
How to use:
Apply generously to face, neck, hands and any other areas at risk of exposure
Apply 30 minutes before sun exposure
Benefits: HIGH UVA PROTECTION
Broad spectrum protection (UVA.UVB. IR-A) 46 PPD. SPF 50+.
Resistent to water, sweat and sand.
No white marks. Non-greasy. Non-sticky.
Minimal formula. Less ingredients, more resistance. Eye safe.
Ultra-resistant formula specifically developed for sensitive skin. A very high protection, broad spectrum (PPD 46, SPF 50+) comfortable fluid formula that is ultra water, sweat and sand resistant. This non-greasy cream does not leave white marks and does not migrate. Non eye-stinging. Broad, photostable UVA/UVB/Infrared protection (PPD 46, SPF 50+). Very high, broad, photostable UVA/UVB/Infrared protection. Optimal SPF 50+ protection reinforced against UVA rays (PPD 46, stricter than the European recommendation) thanks to patented filtering system Mexoplex® combined with La Roche-Posay Thermal Spring Water. DERMATOLOGICALLY TESTED: Anthelios efficacy has been demonstrated via clinical studies carried out in-vivo on subjects suffering from sun intolerances, particularly those caused by UVA rays. Anthelios products all have a high PPD (Persistent Pigment Darkening) factor. The efficacy has been proven by a file of 16 clinical studies carried out by world-renowned expert dermatologists. 9/10 of UK dermatologists would recommend Anthelios.
Discover La Roche-Posay – award-winning French pharmacy skincare for sensitive skin developed with dermatologists. The range addresses a variety of skin concerns such as dryness, blemishesand skin ageing. All products are tested on the most sensitive skin and contain irritation-soothing, anti-oxidant thermal spring water from La Roche-Posay. Extensive research goes into developing our formulations and results are proven through clinical trials, which is why 9/10 UK Dermatologists recommend La Roche-Posay*. *Survey conducted on 267 dermatologists by La Roche-Posay in the UK, July 2019